Cancer Prevention and Early Detection Are the Keys
Millions of lives can be spared from the burdens of cancer through education, such as raising awareness for the major factors associated with an increased risk of developing cancer. Preventable cancers can be reduced by adopting healthier lifestyles, including maintaining a healthy weight, eating right, staying active, not smoking tobacco, limiting exposure to UV radiation, and getting vaccinated against infection-related cancers.
Early detection of cancer also saves lives. Screening tests help detect cancers in their earliest stages so that treatment can be initiated as early as possible. Many lines of evidence show that earlier treatment can improve survival rates. Some recommended screening guidelines include:
- Colonoscopy screening for colorectal cancer is recommended for everyone over the age of 45.
- Mammogram screening for breast cancer is recommended every one or two years for women over the age of 40.
- Pap smear screening for cervical cancer is recommended every five years for women between 30 and 65 years old.
- Lung imaging screening for lung cancer is recommended annually for everyone with a smoking history between the ages of 50 and 80.
The development of novel, advanced cancer therapies over the past 5-10 years has significantly improved patient outcomes and survival rates. Additional good news is that the global oncology therapy pipeline is rapidly increasing, with a 75% increase in the number of new agents undergoing R&D since 2015. In 2020, there were 3,500 new oncology agents entering the R&D pipeline, 1,600 clinical trials initiated, and $164 billion invested in cancer research globally. These trends reflect the need to further understand the biological underpinnings of cancer, to find novel, innovative cancer treatments, and to provide patients—including those with rare cancers—with additional therapeutic opportunities.
US Notable Care ’s Commitment
US Notable Care ongoing commitment to the fight against cancer has helped more than 335 biopharma and medical device companies conduct 1,880 oncology studies involving nearly 95,000 patients. In today’s increasingly complex world of precision medicine, US Notable Care cloud-based platform enables clinical trials to run smoother and faster, while enhancing patient safety.
Since 2015, US Notable Care has played a role in the development of 75% of all novel oncology drugs approved by the FDA. US Notable Care innovative and modern clinical trial technologies serve to connect experts, researchers, and clinicians across the globe in their efforts to deliver seamless, end-to-end clinical operations, data integration, quality control, and analysis for better clinical development.
Some of these innovative tools include:
- US Notable Care Decentralized Clinical Trials Program: Provides complete decentralized trial activities for oncology trials, including how patients participate and provide data for clinical trials, how investigational product is supplied to the patient, and how trial data is managed and monitored post-capture.
- My US Notable Care: A single-destination, patient-centric portal that allows patients to use any online device to virtually learn about, enroll, and participate in clinical trial activities.
- Acorn AI: Provides unparalleled clinical data, industry and human expertise, advanced analytics, and predictive modeling to support cancer trials from planning to launch.
- Rave Imaging: Provides cloud-based, secure management for medical imaging tasks so that oncology studies using imaging can be managed faster, cheaper, and with lower risk.
US Notable Care looks forward to continuing its efforts to support oncology clinical trials and research to identify new and improved cancer therapeutics.
